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Abstract 
BACKGROUND AND OBJECTIVE: This retrospective study analyses the goal assessment 
of the treatment of spasticity. The indications for and the achievement of the goal of 
botulinum toxin injections were compared to orthopedic procedures and others.  
METHODS: A database was created from the patients' medical files. The efficiency of 
treatment was then evaluated using the improvement in the sub-goals of the International 
Classification of Functioning, Disability and Health (ICF): pain (B280-B289), function of the 
joints and bones (B710-B729), improvement of mobility (D450-DN83) and personal 
maintenance (D510-D599). The results are discussed after a literature review.   
RESULTS: The botulinum toxin injection was more common than orthopedic procedures. 
Orthopedic procedures showed a tendency to be more efficient regarding the improvement in 
ICF objectives.  
CONCLUSIONS: This study was unable to prove a statistically significant difference 
between botulinum toxin and orthopedic procedure regarding ICF objectives due to the 
number of subjects being too small. But it showed that 83.4% of patients were treated by 
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botulinum toxin before surgery and only operated in the case of failed goal-achievement. The 
surgery then enabled the goal to be achieved. This systematic goal assessment is necessary in 
order to understand better the efficiency of the management of spasticity treatment methods.  
Keywords: spasticity, management, botulinum toxin, orthopedic procedure 
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Introduction 
Spasticity refers to an abnormal, velocity-
dependent increase in muscle tone 
resulting from interruption of the neural 
circuitry regulating the muscle and is a 
common complication of cerebral palsy, 
brain injuries, spinal cord injuries, multiple 
sclerosis and stroke (Satkunam, 2003). Its 
incidence after a stroke is 17% to  38% 
(Leathley et al., 2004; Lundström, Terént, 
& Borg, 2008). Moreover, the severity of 
spasticity increases over time (Opheim, 
Danielsson, Alt Murphy, Persson, & 
Sunnerhagen, 2014) and induces 
significant pain, contractures, joint 
subluxations or dislocations, peripheral 
neuropathy and pressure ulcers (Gorgey, 
Chiodo, & Gater, 2010).  
The prevention of complications due to 
spasticity is therefore important to improve 
the quality of life of patients. 
Among the different treatments of 
spasticity, botulinum toxin A is a well-
tolerated and effective focal intervention 
for the reduction of spasticity, and it is 
widely recommended in clinical practice 
(Turner-Stokes, Fheodoroff, Jacinto, 
Maisonobe, & Zakine, 2013). Botulinum 
toxin is only reimbursed by Swiss health 
insurance for spasticity due to a stroke and 
the maximal recommended dose per 
session in Switzerland is 400 IU. In some 
cases, repeated administration of 
botulinum toxin leads to the development 
of  resistance due to circulating antibodies 
(Brin, 1997). In many patients, it is not 
possible to treat upper and lower limbs at 
the same time with a sufficient effect. In 
this case, it is possible to propose an 
orthopedic surgical approach to the patient.  
Orthopedic procedures can be classified 
into three major categories: tenotomy, 
tendon transfer and tendon lengthening 
(Jozefczyk, 2002). Tenotomies are 
reserved for the release of the tendon to 
severely spastic muscles (Jozefczyk, 
2002). Tendon lengthening is performed to 
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weaken spastic muscles and position joints 
at a more natural and useful angle 
(Jozefczyk, 2002). Tendon transfers are 
undertaken so that muscles, which remain 
at least partially functional, can produce 
useful movements (Jozefczyk, 2002). 
Tendon lengthening and tendon transfer 
are most successful in the lower extremity 
and tend to improve borderline ambulation 
(Bleck, 1975). 
The management of spasticity needs a 
multidisciplinary approach to define 
treatment goals according to the 
International Classification of Functioning, 
Disability and Health (ICF). The 
assessment of the patient occurs over 
multiple visits to determine the correct 
combination of therapies and procedures to 
achieve the best function (de Roode, 
James, & Van Heest, 2010)   
To fulfil this requirement a spasticity 
outpatient clinic has been developed in the 
Clinique Romande de Réadaptation and in 
the department of Neurology at the 
Lausanne University Hospital (CHUV). 
Both centers use the same scales and 
scores to evaluate  patients. A first 
consultation evaluates the indication for a 
botulinum toxin treatment. When 
conventional treatments such as 
physiotherapy, occupational therapy, 
antispastic drugs or orthosis are 
insufficient to obtain a satisfactory 
improvement there is a neuro-orthopedic 
consultation. A surgical approach is 
discussed in the presence of an orthopedic 
surgeon and a specialist in reconstructive 
and plastic surgery. 
Patients and Methods 
Patients 
Inclusion criteria were to be older than 18, 
to suffer from spasticity and to have been 
evaluated in the interdisciplinary neuro-
orthopedic spasticity clinic in Lausanne 
between December 2003 and November 
2013. The only exclusion criterion was to 
have insufficient information in the 
medical records to complete the database.  
Method  
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As the number of patients was too small to 
be statistically significant it was decided to 
carry out an observational study of a group 
of patients and the treatment they received 
for individual goal assessment. The goal 
assessments were taken from the main 
component of the International 
Classification of Functioning, Disability 
and Health (ICF). The database was 
created using  data from patients' medical 
files of the CHUV in Lausanne, the 
Neurological Centre Plein Soleil in 
Lausanne and the Reeducation Centre in 
Sion. 
The primary outcome was to compare the 
efficiency of treatments in terms of ICF 
goals. For the chapter Body Function and 
Structure the chosen sub-goals for this 
study were improvement in function of the 
joints and bones (B710-B729) and 
decrease of pain (B280-B289). The 
mobility of joints was measured and 
compared before and after treatment. If the 
improvement was judged sufficient for the 
patient, the efficiency of treatment was 
considered as good efficiency. Because 
patients were followed for many years, it 
happened that a treatment with a good 
efficiency when the patient was first 
treated did not work well after a certain 
period. So to distinguish these from 
treatments which maintained  good 
efficiency, they were noted as partially 
efficient. The objective concerning pain 
was evaluated by the patient as good if the 
pain was relieved, partial if the treatment 
had no effect and bad if the treatment made  
the pain worse. The second ICF goal 
assessment  corresponds to two sub-goals 
from activity and participation: mobility 
and self-care. Mobility is affected by 
spasticity in the lower limb(s) and self-care 
mostly concerns hand spasticity. So it was 
interesting to compare both. The 
improvement of mobility is important for 
patients with lower limb spasticity because 
it  limits mobility and reduces quality of 
life (Martin, Abogunrin, Kurth, & Dinet, 
2014). Just as lower limb spasticity affects 
quality of life, upper limb spasticity can 
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have a significant effect on self-care, like 
Toileting (D530) or Washing oneself 
(D510) (World Health Organisation, s. d.). 
Efficiency in terms of self-care and 
mobility were measured in the same way 
as the pain sub-goal: good for an 
improvement, partial if no improvement 
and bad if the situation got worse.  
The secondary outcome was  to compare 
the previous results with results from other 
articles.  
Results 
In total, 102 patients attended  the 
interdisciplinary clinic  from 2003 but 61 
did not have sufficient information in their 
medical records. 47.6% of patients suffered 
from spasticity post-stroke. Of 41 patients 
retained for the study, 78% had botulinum 
toxin treatment and 44% had surgical 
treatment (Figure 1). However, only a few 
patients had surgical treatment without first 
receiving botulinum toxin (7.3%). 
Regarding the indication for treatment, we 
were able to group patients according to 
four ICF goals: lowering pain (B280-
B289), increasing function of the joints and 
bones (B710-B729), increasing walking 
performance (D450-N83) and improving 
personal maintenance (D510-D599) 
(Figure 3). 
The efficiency of decreasing pain was 
good except for 14% who had partial 
efficiency. The efficiency of increasing 
function of the joints and bones was 45% 
good efficiency, 45% partially efficient 
and 10% bad efficiency (Figure 4). 
Botulinum toxin injections accounted for 
84% of the treatments improving function.  
In the improvement of walking, 31% of the 
patients had only botulinum toxin 
injection, 13% only surgery and 54% had 
toxin botulinum injections followed by 
surgery. For surgery the major indication 
for treatment was spastic equinovarus foot: 
the efficiency was good for 73% of the 
patients and partial for 27%. Botox had a 
good efficiency in 31%, partial efficiency 
in 57%, and bad efficiency in 10% (Figure 
4). Regarding an improvement in personal 
maintenance, 44% of patients had surgical 
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treatment. The surgery efficiency was good 
in 50% and partial in 50%. For the botox, 
there was 20% of good improvement, 60% 
partial and 20% bad (Figure 4). 
Discussion 
The botulinum toxin injection treatment 
was the procedure patients in this study 
had the most. It can be explained by the 
fact that botulinum toxin is a safe and 
reversible procedure. Indeed, effects will 
last a few months and if the treatment is 
not satisfying, another procedure can still 
be tried. In our study, the high number of 
patients treated with botulinum toxin can 
also be explained by the type of study. 
Indeed, as a retrospective observational 
study, no randomization had been done and 
the all our patients first went to a spasticity 
clinic to evaluate the indication of a 
botulinum toxin injection. In the literature, 
many articles can be found to prove the 
efficiency and safety of botulinum toxin. 
For example, a retrospective analysis from 
Baricich A et al. (Baricich et al., 2015) 
evaluated the efficacy and safety of high 
doses of botulinum toxin in 26 patients 
affected by upper and/or lower limb post-
stroke spasticity. No adverse events were 
reported and high doses of botulinum toxin 
were shown to be effective and safe.  
The results of the study show that a 
minority of patients had surgical treatment 
but with a better improvement in ICF 
objectives (Figure 2). It can be explained 
by a selection bias, because as surgery 
does not allow an easy way back, the 
surgeon will recommend surgery only for 
patients who he is sure will benefit from it. 
But we also found a study from Van Heest 
AE et al. (Van Heest, Bagley, Molitor, & 
James, 2015) which compared botulinum 
toxin injection treatment, surgical 
treatment and ongoing treatment for 
children with upper-extremity cerebral 
palsy. They demonstrated that surgical 
treatment provides a greater improvement, 
of modest magnitude, than botulinum toxin 
injections or regular, ongoing therapy at 
twelve months. This study could also have 
a selection bias but it was only for children 
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who met standard indications for tendon 
transfer surgery which is also a selection 
bias.  
Regarding the patients' activity, an 
improvement in walking was demonstrated 
by a lot of patients with varus equinus 
spastic foot deformity who had surgical 
treatment. A retrospective study from Vogt 
JC et al.  (Vogt, Bach, Cantini, & Perrin, 
2011) confirms that surgery for 
equinovarus foot can increase the walking 
distance. Of 82 patients who were 
examined up to 65 months after surgery, 
74 reported an increase in their walking 
distance even if moderate. But we also 
found a study which confirms the 
efficiency of botulinum toxin injection for 
equinus foot (Cardoso et al., 2006). So a 
good multidisciplinary evaluation should 
be carried out to find the better 
management depending on the situation.  
To compare improvement in mobility 
which is affected by lower limb spasticity 
and improvement in personal maintenance 
which is affected by upper limb spasticity, 
treatments provided better improvement in 
walking than in personal maintenance. 
Maybe the management of lower limb 
spasticity is better than upper limb 
spasticity, but with such a small number of 
patients, the difference is probably not 
significant. This would be an interesting 
subject to study in a future research 
project.  
 
Conclusion 
This retrospective observational study 
shows that a minority of patients had 
surgical treatment but with better 
improvement in ICF objectives. But as it is 
a safer procedure, with 60% of partial 
success we recommend always trying the 
botox treatment before surgery. Further 
studies with goal assessment are needed 
with  a larger population and prospective 
goal assessment based on ICF evaluation 
should be completed considering the 
individual needs of the patient, taking 
account of the heterogeneous context.  
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